Nab-PTX+GEM+Zolrdronate-activated killer cells

3 trials

Sponsors

Kawasaki Medical School Department of Clinical Oncology, Kawasaki Medical School Department of Clinical Oncology

Conditions

Chemotherapy-naive unresectable or recurrent pancreatic cancer

Unknown Phase

Clinical efficacy of standard chemotherapy plus zoledronate- activated autologous killer lymphocytes (ZAK cells) in patients with unresectable or recurrent pancreas cancer

Active, not recruitingJPRN-UMIN000009462

Kawasaki Medical School Department of Clinical OncologyChemotherapy-naive unresectable or recurrent pancreatic cancer

Start: 2016-10-17Target: 60Updated: 2026-06-29

Clinical efficacy of nab-PTX+GEM chemotherapy plus zoledronate- activated autologous killer lymphocytes (ZAK cells) in patients with unresectable or recurrent pancreas cancer

Active, not recruitingJPRN-UMIN000021827

Kawasaki Medical School Department of Clinical OncologyChemotherapy-naive unresectable or recurrent pancreatic cancer

Start: 2016-10-17Target: 60Updated: 2026-06-29

Clinical efficacy of nab-PTX+GEM chemotherapy plus zoledronate- activated autologous killer lymphocytes (ZAK cells) in patients with unresectable or recurrent pancreas cancer

Active, not recruitingJPRN-UMIN000041683

Kawasaki Medical School Department of Clinical OncologyChemotherapy-naive unresectable or recurrent pancreatic cancer

Start: 2021-01-01Target: 60Updated: 2026-06-29